With around 75,000 new cases per year, breast cancer is by far the most common cancer among women in Germany. Using digital breast tomosynthesis in the breast cancer screening program could prevent around a quarter of invasive interval cancers that occur within two years after a digital mammogram.
Less Can Be More in Breast Cancer Treatment, Precision Oncology Editors Argue Bioengineer.org
Roche gets a lung cancer win with its KRAS drug divarasib STAT
Merck drug extends survival in endometrial cancer trial, wins US priority review Reuters
Laura Esserman Wins 2026 AIM-HI Beacon Award for Breast Cancer Leadership Bioengineer.org
Alliance webinar showcases latest cancer research from 2026 ASCO Meeting Bioengineer.org
National Leader in Cancer Symptom Management, Ishwaria Subbiah, MD, Joins Perlmutter Cancer Center NYU Langone Health
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026. The vaccine, intismeran autogene, was given alongside pembrolizumab and…
New test could flag which men need aggressive prostate cancer treatment and which don't Fox News
«А что, так можно было?» Как «операции Анджелины Джоли» спасают женщин от рака и почему в России они непопулярны Lenta News
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and after prostate cancer surgery was further validated by a substudy…
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.
From Promise to Proof: Personalized Melanoma mRNA Vaccine Delivers Phase III Success American Association for Cancer Research (AACR)
This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent Inc.com